360° SearchNetwork Hot Spots Trends Time Series

budesonide

Type: Keyphrase

Name: budesonide

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Peripheral Blood MDSCs, IL-10 and IL-12 in Children with Asthma and Their Importance in Asthma Development

by Yan-Li Zhang, Bin Luan, Xiu-Fang Wang, Jun-Ying Qiao, Li Song, Rui-Rui Lei, Wei-Xia Gao, Ying LiuObjectiveTo investigate myeloid-derived suppressor cell (MDSC) accumulation and interleukin 10 (IL-10) and interleukin 12 (IL-12) levels during the onset ... [Published Elites TV - May 23 2013]

Entities: IL-12, Asthma, Serum

First reported May 22 2013 - Updated May 23 2013 - 2 reports

Boston Scientific Corp

Boston Scientific Announces Results from Promus Premier; Salix's Budesonide Foam Shows Significant Results

Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS ... [Published BioMedReports - May 23 2013]

Entities: budesonide, Stent, Patient, Boston Scientific Corp

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Capability of hypertonic saline cough provocation test to predict the response to inhaled ...

Many patients with chronic cough respond to treatment with inhaled corticosteroids but it is difficult to predict which patients are likely to respond. The primary aim of the present study was to define the capability of hypertonic saline cough provocation ... [Published 7thSpace - May 20 2013]

Entities: Histamine, Nitric Oxide, Corticosteroid, Leicester

First reported May 19 2013 - Updated May 19 2013 - 1 reports

FDA Food & Drug Administration

Salix Pharmaceuticals Updates on 1Q2013 Results [Professiona. . .

Salix Pharmaceuticals announced financial and operating results for the first quarter ended March 31, and other business updates.In a release on May 9, the Company noted that total product revenue was $202.6 million for the first quarter of 2013, an 18 ... [Published Equities.com - May 19 2013]

Entities: Salix Pharmaceuticals Ltd, Relistor, XIFAXAN, Solesta, FDA Food & Drug Administration

First reported May 17 2013 - Updated May 17 2013 - 2 reports

Santarus Inc

Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting

SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced that additional data from two pivotal clinical studies with UCERIS® (budesonide) extended release tablets will be featured in two poster presentations at the Digestive Disease Week® ... [Published Investors Business Daily - May 17 2013]

Entities: budesonide, Digestive Disease, Santarus Inc

First reported May 13 2013 - Updated May 14 2013 - 1 reports

Assessing Your Asthma is Key to Taking Control PR Newswire

/PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to ... [Published Yahoo! Finance - May 13 2013]

Entities: Symbicort, Corticosteroid, Patient

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Salix Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript

5:00 PM ETOperatorGood afternoon. My name is Jarrod, and I will be your conference operator today. At this time, I would like to welcome everyone to the Salix Pharmaceuticals First Quarter 2013 Earnings Conference Call. [Operator Instructions]Mr. Freeman, ... [Published Seeking Alpha - May 10 2013]

Entities: Salix Pharmaceuticals Ltd, Relistor, Solesta, XIFAXAN, Crohn's disease

First reported May 06 2013 - Updated May 07 2013 - 1 reports

Santarus (SNTS) Tops Q1 EPS by 18c; Boosts FY13 Outlook

In April 2013, announced the submission of a BLA to the FDA for RUCONEST (recombinant human C1 esterase inhibitor) for the treatment of acute attacks of angioedema in patients with HAE.Received FDA approval in January 2013 of UCERIS (budesonide) extended ... [Published Street Insider - May 06 2013]

Entities: Santarus Inc, Patent, gastroenterologist

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

MKSAP: 35-year-old woman with an acute exacerbation of asthma

A 35-year-old woman is evaluated in an urgent care center for an acute exacerbation of asthma. She has a history of frequent asthma exacerbations requiring unscheduled visits; however, between these exacerbations, her examination and pulmonary function ... [Published KevinMD.com - Apr 27 2013]

Entities: budesonide, Albuterol, Social Media

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Earnings battered but AZ optimistic for future growth

AstraZeneca has posted a 13% decline in first-quarter revenues to $6.39 billion, due to the loss of exclusivity on key brands, but analysts believe things are starting to improve at the Anglo-Swedish drugmaker.Core operating profit was down 25% to $2.32 ... [Published Pharma Times - Apr 25 2013]

Entities: Brilinta, AstraZeneca PLC, Pascal Soriot, Crestor

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Stocks in Focus: Swift Transportation, Warner Chilcott, Santarus, InterMune

Lakeway, NY -- (SBWIRE) -- 04/15/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-Swift Transportation Co (NYSE:SWFT) ... [Published SBWire - Apr 15 2013]

Entities: Swift Transportation Company, InterMune Inc, Warner Chilcott plc, Santarus Inc, Doryx

First reported Jan 15 2013 - Updated Jan 16 2013 - 4 reports

4 Healthcare Stock Stories Not to be Missed

St. Jude Medical ( NYSE:STJ ): Closing price $38.37 On Monday, the medical device manufacturer reported that it has received an FDA warning letter in regards to problems with manufacturing and quality control at a California plant where it makes ... [Published Wall St. Cheat Sheet - Jan 15 2013]

Entities: CVS Corporation, budesonide, Johnson & Johnson, Santarus Inc

Quotes

...to our growing pipeline of drug-eluting stent technologies," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "These innovations reflect our commitment to interventional cardiologists and the patients they serve."

Boston Scientific Announces Results from Promus Premier; Salix's Budesonide Foam Shows Significan ... [Published BioMedReports - May 23 2013]

Mesalamine-Related Presentation Poster #Su1222: Lichtenstein et al. "Long-Term Safety and Tolerability of Once-Daily Mesalamine Extended-Release Capsules in Patients with Ulcerative Colitis"

Salix Pharmaceuticals Outlines Data Presentations at Digesti. . . [Published Equities.com - May 22 2013]

"Salix is built on a tremendous history of success - including the approval of nine New Drug Applications, the acquisition/ licensing of 16 products and the establishment of a top-ranked specialty sales force since 2000. We are pleased to announce that in an independent study conducted by IMS, for 2012 gastroenterologists rated the Salix sales force number one with respect to impact, quality and familiarity. Our core business remains strong and continues to grow. Our portfolio of marketed products is complemented by our impressive pipeline of product candidates in development that should drive additional revenue growth over the long term as they are commercialized. Additionally, the Company continues to actively pursue additional product and acquisition opportunities to expand and broaden our product portfolio. We are extremely pleased with the success we have achieved to date, and we believe the Company is well-positioned to continue to succeed in our mission of being the leading specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders."

Salix Pharmaceuticals Updates on 1Q2013 Results [Professiona. . . [Published Equities.com - May 19 2013]

"Some 235 million people worldwide suffer from this non communicable disease" says Isaac

Malawi struggles with asthma [Published Malawi Daily Times - May 14 2013]

More Content

sort by: Date \| Relevance
Peripheral Blood MDSCs, IL-10 and IL-12 in Chil... [Published Elites TV - May 23 2013]
Boston Scientific Announces Results from Promus... [Published BioMedReports - May 23 2013]
Salix Pharmaceuticals Outlines Data Presentatio... [Published Equities.com - May 22 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Amarin... [Published Proactiveinvestors United Kingdom RSS feed - May 22 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Amarin... [Published Proactiveinvestors United Kingdom RSS feed - May 22 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Amarin... [Published Proactiveinvestors United Kingdom RSS feed - May 22 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Amarin... [Published Proactiveinvestors United Kingdom website - May 22 2013]
Salix Pharma Says Results for Budesonide Foam S... [Published Benzinga.com - May 22 2013]
Salix Pharmaceuticals Announces Statistically S... [Published Business Wire Health News - May 22 2013]
Regeneron Eyes Potential Blockbuster With Asthm... [Published Xconomy - May 22 2013]
Santarus, Inc. (SNTS) Is a Real Gas! [Published InsiderMonkey.com - May 21 2013]
Santarus Is a Real Gas! [Published Motley Fool - May 21 2013]
Capability of hypertonic saline cough provocati... [Published 7thSpace - May 20 2013]
Salix Pharmaceuticals Updates on 1Q2013 Results... [Published Equities.com - May 19 2013]
Celsion Shares Moving Higher on Findings from T... [Published BioMedReports - May 18 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Investors Business Daily - May 17 2013]
Santarus (SNTS) to Present Additional Data on U... [Published Street Insider - May 17 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire - May 17 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire Science: Science News - May 17 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire Health News - May 17 2013]
Santarus' CEO Presents at Bank of America/Merri... [Published Seeking Alpha - May 17 2013]
2 Healthcare Companies With Recent Intensive In... [Published Seeking Alpha - May 16 2013]
Santarus Announces Exercise in Full of Option t... [Published TradingCharts.com - May 15 2013]
Malawi struggles with asthma [Published Malawi Daily Times - May 14 2013]
Salix Beats on Earnings Zacks [Published Yahoo! Finance - May 14 2013]
Assessing Your Asthma is Key to Taking Control [Published KTVN - May 13 2013]
Assessing Your Asthma is Key to Taking Control ... [Published Yahoo! Finance - May 13 2013]
Assessing Your Asthma is Key to Taking Control [Published ADVFN India - May 13 2013]
Vectura, Chinese Partners Form $65M Respiratory JV [Published Genetic Engineering News - May 13 2013]
Vectura establishes strategic partnership in China [Published Manufacturing Chemist - May 13 2013]

Blogs

sort by: Date \| Relevance
US EQUITIES OPENING HEADLINES INCLUDING: Amarin... [Published Proactiveinvestors United Kingdom website - May 22 2013] US equity futures point to a marginally higher open on Wall Street although have been trading in thin volumes throughout the day as market participants sit on the sidelines ahead of key risk events later in the session. Fed chairman Bernanke is due ...
MKSAP: 35-year-old woman with an acute exacerba... [Published KevinMD.com - Apr 27 2013] A 35-year-old woman is evaluated in an urgent care center for an acute exacerbation of asthma. She has a history of frequent asthma exacerbations requiring unscheduled visits; however, between these exacerbations, her examination and pulmonary function ...
Pending EC decision: Labazenit , budesonide/sal... [Published Pending EC decisions and European Public Assess ... - Mar 22 2013]
Santarus Earnings: Here’s Why the Stock is Risi... [Published Wall St. Cheat Sheet - Mar 04 2013] Santarus Inc. ( NASDAQ:SNTS ) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 10.51%. The stock market ...
Santarus launches new ulcerative colitis therapy [Published PBR - News - Feb 15 2013] Specialty biopharmaceutical company Santarus has announced the commercial launch of ulcerative colitis therapy, Uceris (budesonide) extended release tablets. ...

Press Releases

sort by: Date \| Relevance
Salix Pharmaceuticals Announces Statistically S... [Published Business Wire Health News - May 22 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire - May 17 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire Science: Science News - May 17 2013]
Santarus Announces UCERIS (budesonide) Poster P... [Published Business Wire Health News - May 17 2013]
Santarus Announces Launch of a Proposed Seconda... [Published Business Wire - May 09 2013]